Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Intensity Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

POSTER PS5-08-16 REPORTS EARLY OBSERVATIONS FROM THE INVINCIBLE-4 STUDY, AN ONGOING RANDOMIZED, PRESURGICAL PHASE 2 CLINICAL TRIAL FOR TRIPLE NEGATIVE BREAST CANCER CONTINUE TO SHOW FAVORABLE SAFETY 50% FEWER GRADE 3 OR HIGHER ADVERSE EVENTS WERE OBSERVED IN THE INT230-6 COHORT COMPARED TO THE STANDARD OF CARE ("SOC") NEOADJUVANT CHEMOTHERAPY ALONE COHORT. POSTER PS4-10-15 DESCRIBES AN OVERVIEW OF A POTENTIAL PHASE 3 CLINICAL STUDY DESIGN WITH INT230-6 PLUS STANDARD OF CARE WITH AND WITHOUT THE TOXIC ANTHRACYCLINE, DOXORUBICIN SHELTON, CONN.

INTENSITY THERAPEUTICS, INC. TO PRESENT TWO POSTERS AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM

SHELTON, CONN. , DEC. 5, 2025 /PRNEWSWIRE/ --INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY ANNOUNCED THAT IT HAS BEEN GRANTED A 180 CALENDAR DAY EXTENSION FROM THE NASDAQ STOCK MARKET LLC ("NASDAQ") TO REGAIN COMPLIANCE WITH THE NASDAQ'S MINIMUM $1.00 BID PRICE REQUIREMENT SET FORTH IN NASDAQ LISTING RULE 5550(A)(2) (THE "RULE") FOR CONTINUED LISTING ON NASDAQ (THE "MINIMUM BID PRICE REQUIREMENT"), FOLLOWING THE EXPIRATION OF THE INITIAL 180 CALENDAR DAY PERIOD TO REGAIN COMPLIANCE ON DECEMBER 3, 2025, WHICH WAS INITIALLY GRANTED ON JUNE 6, 2025.

INTENSITY THERAPEUTICS GRANTED 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT

SHELTON, CONN. , DEC. 4, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR "THE COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY CANCER THERAPIES USING ITS NON-COVALENT, DRUG-CONJUGATION TECHNOLOGY THAT CREATES DRUG PRODUCTS DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, TODAY ANNOUNCES TWO PRESENTATIONS AT THE UPCOMING 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS), IN SAN ANTONIO, TX ON DECEMBER 9-12, 2025.

INTENSITY THERAPEUTICS ANNOUNCES TWO PRESENTATIONS AT THE UPCOMING 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM

THE COMPANY EXPECTS TO FILE A PROTOCOL AMENDMENT IN THE INVINCIBLE-4 STUDY TO REVISE THE DOSING REGIMEN FOR THE INT230-6 TREATMENT COHORT, AND TO REINITIATE PATIENT ENROLLMENT IN THE FIRST QUARTER OF 2026 IT-01 STUDY MANUSCRIPT PUBLISHED, FEATURING A COMPREHENSIVE EVALUATION OF DATA, INCLUDING DISEASE CONTROL RATE, OVERALL SURVIVAL, IMMUNE ACTIVATION, ABSCOPAL EFFECTS, TUMOR NECROSIS, DOSE RANGING, AND SAFETY $7.1 MILLION CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2025, WITH AN INCREMENTAL $6.1 MILLION RAISED IN THE FOURTH QUARTER OF 2025 CASH RUNWAY EXTENDED UNTIL THE END OF THE FIRST QUARTER OF 2027 SHELTON, CONN. , NOV. 6, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.

INTENSITY THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

SHELTON, CONN. , OCT. 31, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH A NEW LONG-TERM FUNDAMENTAL INVESTOR FOR THE PURCHASE AND SALE OF 5,000,000 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $0.80 PER SHARE, IN A REGISTERED DIRECT OFFERING, FOR GROSS PROCEEDS OF APPROXIMATELY $4 MILLION, BEFORE DEDUCTING PLACEMENT AGENT COMMISSIONS AND OTHER OFFERING EXPENSES.

INTENSITY THERAPEUTICS, INC. ANNOUNCES PRICING OF $4 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK

THE PAPER FEATURES A COMPREHENSIVE EVALUATION OF DATA, INCLUDING DISEASE CONTROL RATE, OVERALL SURVIVAL, IMMUNE ACTIVATION, ABSCOPAL EFFECTS, TUMOR NECROSIS, DOSE RANGING, AND SAFETY THE MANUSCRIPT IS OPEN ACCESS THE COMPANY WILL HOST A WEBINAR WITH THE PAPER'S LEAD AND SENIOR AUTHORS FROM THE UNIVERSITY OF SOUTHERN CALIFORNIA TO DISCUSS THE RESULTS ON FRIDAY, OCTOBER 31, 2025, AT 9:00 AM (SEE BELOW) SHELTON, CONN. , OCT. 30, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR "THE COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY CANCER THERAPIES USING ITS NON-COVALENT, DRUG-CONJUGATION TECHNOLOGY THAT CREATES DRUG PRODUCTS DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, ANNOUNCES THAT EBIOMEDICINE, A LANCET DISCOVERY SCIENCE JOURNAL, HAS PUBLISHED THE COMPANY'S PHASE 1/2 IT-01 CLINICAL STUDY MANUSCRIPT FOR THE TREATMENT OF METASTATIC OR REFRACTORY CANCERS.

INTENSITY THERAPEUTICS, INC. ANNOUNCES PUBLICATION OF CLINICAL RESULTS OF INT230-6 FOR THE TREATMENT OF METASTATIC OR REFRACTORY CANCERS IN EBIOMEDICINE, A LANCET DISCOVERY SCIENCE JOURNAL

Intensity Therapeutics, Inc.

INTS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Intensity Therapeutics, Inc.

INTS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INTS